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Wegener’s granulomatosis, microscopic polyangiitis,
Churg-Strauss syndrome, and idiopathic pauci-im-
mune necrotizing crescentic glomerulonephritis are
associated with myeloperoxidase (MPO)-specific anti-
neutrophil cytoplasmic autoantibodies (ANCAs). Clin-
ical and experimental evidence indicates that ANCA
and proinflammatory stimuli of infectious origin act
synergistically to cause vasculitis. We tested this hy-
pothesis in a recently developed mouse model of anti-
MPO IgG-induced glomerulonephritis by using bacte-
rial lipopolysaccharide (LPS) as the proinflammatory
stimulus. Systemic administration of LPS dose depen-
dently increased renal injury induced by anti-MPO
IgG as demonstrated by increased glomerular cres-
cent formation and glomerular necrosis. In the early
phase, LPS enhanced anti-MPO IgG-induced glomeru-
lar neutrophil accumulation. Furthermore, a tran-
sient induction of circulating tumor necrosis factor
(TNF)- levels, followed by a marked increase in cir-
culating MPO levels, was observed on administration
of LPS. In vitro , anti-MPO IgG induced a respiratory
burst in murine neutrophils only after priming with
TNF-. Finally, anti-TNF- treatment attenuated, but
did not prevent, the LPS-mediated aggravation of anti-
MPO IgG-induced glomerulonephritis. In conclusion,
our study demonstrates that ANCA and proinflamma-
tory stimuli act synergistically to induce vasculitic
disease and suggests potential benefits of inhibiting
TNF- bioactivity in treating human ANCA-associated
necrotizing crescentic glomerulonephritis. (Am J
Pathol 2005, 167:47–58)
Wegener’s granulomatosis, microscopic polyangiitis,
Churg-Strauss syndrome, and idiopathic pauci-immune
necrotizing crescentic glomerulonephritis (NCGN) are
forms of small-vessel vasculitis of unknown etiology that
are strongly associated with anti-neutrophil cytoplasmic
autoantibodies (ANCAs).1 ANCAs comprise a group of
autoantibodies directed against proteins contained in the
lysosomal compartments of neutrophils and monocytes.
The primary target antigens have been identified as pro-
teinase 3 (Pr3), a 29-kd neutral serine proteinase, and
myeloperoxidase (MPO), a 140-kd protein involved in the
generation of reactive oxygen species.2 To date, detec-
tion of ANCAs has proven to be a helpful diagnostic tool
and many clinical studies have confirmed that Pr3-ANCA
and MPO-ANCA are highly specific for Wegener’s gran-
ulomatosis and microscopic polyangiitis, respectively.2
Since the discovery of ANCAs, numerous clinical and
laboratory studies have been performed to determine
whether ANCAs are directly involved in the pathogenesis
of vasculitis and glomerulonephritis. The overall concept
derived from these studies is that ANCA-induced vascu-
litis is a two-hit process in which ANCAs together with
proinflammatory stimuli, most likely of infectious origin,
are required for the induction of full-blown disease. In
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support of this model are clinical observations dem-
onstrating that relapses in disease activity are often
preceded by rising ANCA levels.3–5 Furthermore, the
frequent observation of infectious episodes before diag-
nosis and/or relapse suggests that these may play a role
in the pathogenesis of ANCA-associated disease.6–9
Consistent with these clinical observations are in vitro
studies that have shown that ANCAs are capable of
activating neutrophils and monocytes primed with proin-
flammatory cytokines, resulting in an oxidative burst, de-
granulation, production of cytokines, and endothelial cell
damage.10–15
Recently, an experimental animal model of anti-MPO-
induced NCGN was developed that involves the adoptive
transfer of mouse MPO-reactive splenocytes into im-
mune-deficient mice.16 These mice developed severe
NCGN with pathological features that were remarkably
similar to human anti-MPO-associated glomerulonephri-
tis. In addition, it was demonstrated that passive transfer
of murine anti-mouse MPO antibodies alone into either
immune-deficient or wild-type (WT) mice also induces
NCGN, although of a substantially milder form. Thus, the
association between ANCAs, small vessel vasculitis, and
infections suggests that, besides ANCAs, a second (non-
specific) proinflammatory signal is necessary to induce
full-blown disease. To test this hypothesis, we used the
experimental mouse model of anti-MPO antibody-in-
duced NCGN and investigated the effects of bacterial
lipopolysaccharide (LPS), as a model (pro-) inflammatory
stimulus, on disease severity.
Materials and Methods
Mice
Mpo/ mice, backcrossed to a C57BL/6 background for
six times, were genotyped using polymerase chain reac-
tion-amplified DNA from tail clippings.17 WT female
C57BL/6 (8 to 12 weeks of age) were obtained from
Harlan (Horst, The Netherlands). Mice were kept accord-
ing to University of Maastricht animal facility regulations,
and all experiments were approved by the local Animal
Care and Experimentation Committee.
Purification of Murine MPO
Murine MPO (muMPO) was purified from WEHI-3, a my-
eloid cell line, that was grown in HEPES-buffered
McCoy5A medium containing penicillin/streptomycin and
10% fetal calf serum. When a density of 1.5  106 cells/ml
was reached, cells were harvested, resuspended in
buffer A containing 6.7 mmol/L sodium acetate, 3.0
mmol/L MgCl2, 3.0 mmol/L NaCl, 0.5 mmol/L phenyl-
methyl sulfonyl fluoride, and 1% CTAB, and lysed by
Dounce homogenization on ice. After stirring (2 hours,
4°C), insoluble particles were removed by centrifugation
(14,000  g, 30 minutes, 4°C), and the supernatant was
dialyzed overnight at 4°C against buffer B containing 100
mmol/L sodium acetate (pH 6.3) and 100 mmol/L NaCl.
Next, CaCl2, MgCl2, and MnCl2 were added to a final
concentration of 1 mmol/L each, and the solution was
mixed with concanavalin A-Sepharose (Amersham Bio-
sciences, Roosendaal, The Netherlands). After centrifu-
gation and removal of supernatant, the concanavalin A
was resuspended in several washes of buffer B with 750
mmol/L methyl -D-mannopyranoside to elute the MPO
(overnight, 4°C). The samples of buffer B containing MPO
(as judged by OD at 428 nm) were then dialyzed against
buffer C, containing 50 mmol/L sodium acetate (pH 8.5
to 9) and 100 mmol/L NaCl, loaded onto a Mono S
cation exchange column (Bio-Rad, Veenendaal, The
Netherlands), eluted with 1 mol/L NaCl, and dialyzed
against phosphate-buffered saline (PBS). Purity was
checked by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis.
Preparation of Pathogenic Mouse Anti-Murine
MPO IgG and Control Mouse Anti-Bovine
Serum Albumin (BSA) IgG
Mpo/ mice were immunized as reported previously16
with minor modifications. Briefly, mice received an intra-
peritoneal injection of 10 g of muMPO in complete
Freund’s adjuvant (Difco, Detroit, MI) on day 0, followed
by intraperitoneal booster injections in incomplete
Freund’s adjuvant on days 21 and 36. On day 42, blood
was obtained and mice were sacrificed. Antibody titers
were monitored by enzyme-linked immunosorbent assay
(ELISA) as described previously.16 In short, microtiter
plates were coated overnight with muMPO (0.5 g/ml)
and blocked with BSA. Then plates were incubated with
mouse sera (1:100 starting dilution), followed by incuba-
tion with alkaline phosphatase-conjugated goat anti-
mouse IgG antibodies. 4-Nitrophenyl phosphate (pNPP)
was used as substrate, and wells were analyzed spec-
trophotometrically at 405 nm.
To obtain anti-BSA IgG, a separate group of Mpo/
mice was immunized with BSA following the protocol
described above. Normal serum from C57BL/6 mice was
obtained from Harlan. IgG was isolated from pooled sera
by 50% ammonium sulfate precipitation followed by pro-
tein G column affinity chromatography. IgG-containing
fractions were concentrated by ultrafiltration (Centriplus;
Millipore, Amsterdam, The Netherlands) and dialyzed
against PBS. Protein concentrations were determined us-
ing the bicinchoninic acid protein assay kit (Pierce, Rock-
ford, IL). The anti-MPO titer of each batch was checked
by ELISA as described above, using a sample of anti-
MPO IgG with previously established pathogenicity as a
reference. Endotoxin concentrations were determined by
the limulus amebocyte lysate assay (BioWhittaker, Walk-
ersville, MD) and depending on the isolation ranged from
0.04 ng/ml to 1.2 ng/ml.
Induction of Glomerulonephritis by Passive
Transfer of Anti-MPO IgG
C57BL/6 mice received a dose of 100 g/g body weight
of sterile-filtered (0.2 m filter; Schleicher & Schuell, Das-
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sel, Germany) anti-MPO IgG by intraperitoneal injection.
Where stated, groups of mice additionally received a
single intraperitoneal injection of 5.0, 0.5, or 0.05 g/g of
LPS (Escherichia coli, serotype 026-B6, n  4 to 5 in each
group; Sigma, St. Louis, MO) dissolved in sterile PBS 1
hour after the administration of IgG. Control mice were
injected with anti-BSA IgG (100 g/g, n  5) followed by
5.0 g/g of LPS 1 hour later, or with LPS (5.0 g/g, n  4)
alone. Circulating anti-MPO IgG was monitored by ELISA
as described above, using a serum pool from MPO-
immunized Mpo/ mice as reference. Results are ex-
pressed as a percentage of the absorbance units (OD
405 nm) of a positive control pool serum.
Measurement of Serum MPO and Tumor
Necrosis Factor (TNF)- Levels
In a separate experiment, the effect of intraperitoneal
injection of LPS on serum TNF- and MPO levels was
determined. Blood was taken from mice 1 week before, 1
hour after, and 1 and 6 days after the administration of
0.05, 0.5, or 5.0 g/g LPS (n  4 in each group) in
endotoxin-free 0.9% saline. Samples were centrifuged
and serum was taken and stored at 20°C. To detect
circulating MPO, we generated a mouse anti-mouse MPO
monoclonal antibody (mAb) from splenocytes obtained
from muMPO-immunized Mpo/ mice using standard
procedures. The resulting mAb (IgG1, designated 8F4)
recognized murine MPO and cross-reacted with rat but
not human MPO as determined by direct ELISA and
immunohistochemistry on normal spleen sections (data
not shown). Using this antibody, a catching ELISA was
developed for the detection of murine MPO in sera as
follows. Microtiter plates were coated with Fc fragment-
specific goat anti-mouse IgG (3.2 g/ml, 100 l/well;
Jackson ImmunoResearch), incubated for 48 hours at
4°C, and blocked with 1% BSA in PBS for 30 minutes at
room temperature. Plates were then incubated with 8F4
(1.0 g/ml, 100 l/well) for 1 hour at room temperature.
Next, plates were incubated with appropriately diluted
serum samples for 1 hour at room temperature, followed
by incubation with polyclonal rabbit anti-human MPO (14
g/ml; DakoCytomation, Glostrup, Denmark) for 1 hour at
room temperature and incubation with alkaline phospha-
tase-labeled polyclonal goat anti-rabbit IgG for 1 hour at
room temperature. Finally, plates were incubated with
pNPP for 30 minutes, and results were analyzed spectro-
photometrically at 405 nm. Concentrations were calcu-
lated from a standard curve of purified murine MPO
(range, 2.5 to 100 ng/ml).
TNF- levels were determined by capture ELISA as
described previously.18 Briefly, plates were coated over-
night with TN3 (5 g/ml). After blocking with BSA, sam-
ples were added to the plate for 1 hour at room temper-
ature. Plates were then incubated for 1 hour with rabbit
anti-mouse TNF polyclonal antibody followed by incuba-
tion with peroxidase-labeled goat anti-rabbit IgG for 1
hour. The assay was developed with O-phenylene dia-
mine, the reaction was stopped with 4 N H2SO4, and the
OD was measured at 490 nm. Concentrations were cal-
culated from a standard curve of recombinant murine
TNF- (range, 0.02 to 40 ng/ml).
Anti-TNF- Treatment
To investigate the effects of TNF- depletion on disease
induction, groups of mice received a single intraperito-
neal dose of the anti-murine TNF- antibody TN3 (500
g/mouse, endotoxin concentration 10 pg/ml), a
complementarity-determining regions-grafted murine
IgG2a (n  8; kindly provided by Celltech, Slough, UK) or
isotype control (mAb L2-3D9, endotoxin concentration
10 pg/ml, n  7),19,20 in sterile PBS, 24 hours before
anti-MPO IgG and LPS (0.5 g/g) administration. When
given 24 hours in advance, this dose of TN3 completely
inhibited TNF- activity in sera of mice taken 1 hour after
intraperitoneal injection of 0.5 g/g LPS, as determined
by cytotoxicity assay using the murine fibrosarcoma cell
line WEHI 164 as described previously.21 All mice were
sacrificed 6 days after disease induction.
Laboratory and Pathological Evaluation of
Disease Induction
At the times indicated, mice were bled and sacrificed.
Urine samples were tested by dipstick (Bayer, Mijdrecht,
The Netherlands) for hematuria, proteinuria, and leuko-
cyturia and scored on a 0 to 4 scale. Blood urea nitro-
gen and creatinine levels were determined in sera col-
lected at the time of sacrifice by an enzymatic
degradation assay on a Synchron LX20 PRO (Beckman
Coulter Inc., Fullerton, CA). Tissue samples were taken
from both kidneys and processed for light microscopy,
immunofluorescence, and immunohistochemistry. For
light microscopy, renal tissue samples were fixed in 4%
formaldehyde and embedded in paraffin. Sections (1.5
m) were cut and hematoxylin and eosin (H&E) and
periodic acid-Schiff staining were performed. For each
animal, a crescent score was determined by evaluating
crescent formation in 50 consecutive glomerular cross
sections. Only glomeruli that had two or more layers of
cells in Bowman’s space were considered crescentic.
Similarly, a glomerular necrosis score was determined for
each animal by evaluating segmental or global glomeru-
lar capillary necrosis in 50 consecutive glomerular cross
sections. Analysis was performed in a blinded manner
using coded slides.
Phenotypic analysis of the inflammatory cell infiltrate
was performed on 4-m cryostat sections fixed in 100%
acetone at room temperature. The following primary an-
tibodies were used: rat anti-mouse CD45, rat anti-mouse
neutrophils (clone NIMP-R14),22 rat anti-mouse CD68
(macrophages, clone FA11),23 and rat anti-mouse CD3
(clone KT3). Endogenous peroxidase activity was
blocked with 0.05% H2O2 in PBS. Rabbit anti-rat IgG-PO
and goat anti-rabbit IgG-PO (both DakoCytomation) were
used as secondary and tertiary antibodies, respectively.
Antibody binding was visualized using 3-amino-9-ethyl-
carbazole and H2O2 as substrates. Sections were coun-
terstained with hematoxylin. Glomerular cell infiltrates
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were determined by counting the number of positive cells
in 30 glomerular cross sections per kidney section. In
experiments in which effects of LPS on early (day 1)
neutrophil recruitment were studied the number of glo-
meruli containing neutrophil aggregates was also scored.
An aggregate was defined as a homotypic aggregate of
three or more neutrophils and was evaluated in 30 glo-
merular cross sections.
Mouse IgG and fibrin deposits were detected by im-
munofluorescence using rabbit anti-mouse IgG-Alexa
Fluor 488 (Molecular Probes, Leiden, The Netherlands)
and rabbit anti-human fibrinogen-fluorescein isothiocya-
nate (DakoCytomation). MPO deposits were detected us-
ing biotinylated mouse anti-mouse MPO (8F4) followed
by streptavidin-Alexa 488 (Molecular Probes). Endoge-
nous avidin and biotin were blocked using a streptavidin/
biotin blocking kit (Vector Laboratories, Burlingame, CA).
Superoxide Anion Assay
To determine the in vitro capacity of polyclonal mouse
anti-murine MPO antibodies to induce an oxidative burst
in murine neutrophils, we used the superoxide dismutase
inhibitable (SOD) ferricytochrome C assay.24 Peritoneal
exudate cells (PECs) were obtained by flushing of the
peritoneal cavities of three to four WT or Mpo/ mice
with sterile Hanks’ balanced salt solution (HBSS) 4 hours
after intraperitoneal administration of 1 ml of 3% thiogly-
collate. As determined on May Grünwald Giemsa-stained
cytospots, the percentage of neutrophils in these cell
preparations was 55%. Cells were centrifuged and re-
suspended at a concentration of 2  106 cells/ml in
HBSS. The remainder of the procedure was performed at
37°C. Cells were incubated with cytochalasin B (5 g/ml;
Serva, Heidelberg, Germany) for 5 minutes, followed by
incubation with recombinant murine TNF- (10 ng/ml;
R&D, Abingdon, UK) or an equal volume of HBSS for 10
minutes. Next, 96-well microtiter plates were incubated
with 200 l of cell suspension (4  105 cells/well), ferri-
cytochrome C (70 mol/L; Sigma, Zwijndrecht, The Neth-
erlands), stimulus, and either SOD (42 U/ml, Sigma) or an
equal volume of HBSS. As stimulus, 250 g/ml of anti-
muMPO IgG or normal mouse IgG was used. Phorbol
ester myristate acetate (200 ng/ml, Sigma) served as a
positive control. Optical density at 550 nm was measured
every 15 minutes for 60 minutes and SOD-inhibitable
production of superoxide was determined as OD at 550
nm. Each test was performed in triplicate and experi-
ments were repeated three (Mpo/ cells) to four (WT
cells) times.
Statistical Analysis
Data are expressed as means  SD and were analyzed
using the unpaired two-tailed Student’s t-test using
Graphpad Prism 4.01 for Windows (Graphpad Software,
San Diego CA). For semiquantitative data from dipstick
analysis, a ranked analysis of variance test was used to
evaluate differences across all groups. When significant
differences were detected with analysis of variance, the
Duncan test was used to evaluate statistical differences
between specific groups. A P value 0.05 was consid-
ered statistically significant.
Results
Development of Circulating MPO-ANCA and
Urinary Abnormalities after Passive Transfer of
Anti-MPO IgG
On passive transfer of anti-MPO IgG, circulating anti-MPO
antibodies were detected in all subjected mice. The level of




(%AU (OD 405 nm) of
positive control)
Day 1 Day 6
Anti-MPO 5 85.2  10.0 54.4  12.2
Anti-MPO  5 g/g LPS 5 77.4  13.5 38.2  8.1*
Anti-MPO  0.5 g/g LPS 5 83.6  2.7 45.0  16.2
Anti-MPO  0.05 g/g LPS 4 82.5  3.1 59.0  6.8
Anti-BSA  LPS 5 g/g 5 0 0
*P  0.04 compared to anti-MPO alone.
Table 2. Urinalysis and Renal Function at 6 Days after Disease Induction





Anti-MPO 5 2.7 2.8 0.8 15.6  7.0 8.1  2.9
(1–3) (2–4) (0–2)
Anti-MPO  5 g/g LPS 5 3.4* 2.6 1.4 19.2  2.6 8.0  0.9
(3–4) (2–3) (0–2)
Anti-MPO  0.5 g/g LPS 5 3.8* 3.2 2.6† 18.2  2.4 7.5  1.8
(3–4) (2–4) (2–3)
Anti-MPO  0.05 g/g LPS 4 2.3 2.3 1.0 21.3  2.6 7.0  1.6
(1–3) (1–3) (1–2)
Anti-BSA  LPS 5 g/g 5 0 1.4 0 18.5  2.4 8.6  1.1
(1–2)
Hematuria, proteinuria, and leukocyturia were tested by dipstick and scored on 0 to 4 scale. Values represent mean scores per group. Samples
taken before antibody injection showed mean proteinuria 1.0, hematuria 0, and leukocyturia 0.
*P  0.005.
†P  0.008.
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circulating anti-MPO was highest on day 1 and had de-
clined at the time of sacrifice (day 6). On day 1, no differ-
ences were detected in levels of circulating anti-MPO anti-
bodies between the experimental groups (Table 1).
However, on day 6, mice that received the highest dose of
LPS (5 g/g) had a significantly lower anti-MPO titer com-
pared to mice receiving anti-MPO alone (Table 1). No anti-
MPO reactivity was detected in sera from mice treated with
anti-BSA IgG and LPS (0.5 g/g) or LPS alone.
By day 1, hematuria had developed in all mice that
received anti-MPO antibodies with or without LPS, which
persisted until the time of sacrifice at day 6 (Table 2).
Most of these mice also had proteinuria and leukocyturia
at day 6. Hematuria and leukocyturia measured at day 6
tended to be more severe in mice treated with anti-MPO
IgG and 5.0 g/g or 0.5 g/g LPS, than in mice treated
with anti-MPO IgG alone (Table 2). At day 6, serum
creatinine and blood urea nitrogen levels were within
normal range in all mice. No urinary abnormalities above
background could be detected in mice treated with anti-
BSA and 5.0 g/g LPS, or with LPS alone (Table 2).
LPS Aggravates Anti-MPO IgG-Induced NCGN
Intraperitoneal administration of anti-MPO IgG into WT
mice induced a focal and segmental NCGN in all sub-
jected mice at day 6, with a mean of 5.6% (range, 2 to
10%) crescentic and 9.0% (range, 7 to 12%) necrotic
glomeruli (Figures 1 and 2). Administration of 5.0 or 0.5
g/g LPS 1 hour after administration of anti-MPO IgG
resulted in a marked increase in the severity of glomeru-
lonephritis, as judged by the percentage of glomeruli
containing crescents or fibrinoid necrosis. Addition of 5.0
g/g LPS resulted in 20.4% (range, 16 to 26%) crescentic
and 22.8% (range, 12 to 36%) necrotic glomeruli,
whereas addition of 0.5 g/g LPS resulted in 20.8%
(range, 14 to 26%) crescentic and 28.4% (range, 22 to
34%) necrotic glomeruli (Figures 1 and 2). Addition of
0.05 g/g LPS did not lead to more severe disease
compared to anti-MPO IgG alone, and administration of
100 g/g anti-BSA IgG and 5.0 g/g LPS, or LPS alone,
did not result in any histological abnormalities (Figures 1
and 2).
Phenotypic analysis of the inflammatory cell infiltrate 6
days after administration of anti-MPO IgG demonstrated
intraglomerular influx of CD45ve leukocytes, the major-
ity of which were found to be FA11 macrophages (Fig-
ure 3, A and B; Table 3). A further increase in the number
of glomerular infiltrating CD45 leukocytes and FA11
macrophages was observed on addition of 5.0 or 0.5
g/g LPS (Figure 3, C to F; Table 3). At this time point,
numbers of intraglomerular CD3 T cells and neutrophils
were only slightly elevated in anti-MPO-treated mice with
or without LPS as compared to nontreated C57BL/6 mice
or mice that had received LPS (5.0 g/g) alone. Immu-
nofluorescence revealed marked focal and segmental
glomerular deposition of fibrin in anti-MPO-treated mice
with or without LPS at day 6 that corresponded with sites
of segmental necrosis or crescent formation (Figure 3I).
In contrast, on day 6 glomerular staining for MPO and IgG
was absent or scanty (Figure 3, G and H).
LPS Enhances Anti-MPO IgG-Induced Early
Neutrophil Recruitment
At day 1, anti-MPO IgG-treated mice showed increased
glomerular influx of neutrophils that occasionally appeared
as small neutrophilic aggregates (Figure 4B). This early
glomerular influx of neutrophils was markedly enhanced on
addition of 0.5 g/g LPS resulting in large neutrophilic ag-
gregates (Figure 4C). In contrast, injection of 0.5 g/g LPS
alone induced only a slight increase in the number of intra-
Figure 1. Effect of LPS on pathological findings in C57BL/6 mice 6 days after
passive transfer of anti-MPO IgG. A: Glomerular crescent formation ex-
pressed as a percentage of glomerular crescents in each animal. *P  0.0005,
**P  0.0002 compared to anti-MPO IgG alone. B: Glomerular necrosis
expressed as a percentage of glomeruli with necrosis in each animal. Hori-
zontal lines represent mean percentages in each group. *P  0.02, **P 
0.001 compared to anti-MPO IgG alone.
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glomerular neutrophils, whereas glomerular neutrophil ag-
gregation was not observed (Figure 4).
LPS Increases Serum MPO and TNF- Levels
In a separate experiment, the effect of a single dose of 5.0,
0.5, or 0.05 g/g LPS on serum MPO and TNF- levels was
determined. As shown in Figure 5, intraperitoneal adminis-
tration of 5.0, 0.5, and 0.05 g/g LPS led to a rise in serum
TNF- levels 1 hour after injection. In case of the high (5.0
g/g) and medium (0.5 g/g) dose of LPS, this was fol-
lowed by a rise in serum MPO levels at day 1. TNF- levels
were undetectable at day 1 and day 6 after administration,
whereas at the latter time point MPO levels had returned to
baseline. Administration of saline alone did not lead to al-
terations in TNF- and MPO levels (data not shown).
Pretreatment with Anti-TNF- Antibody
Attenuates Glomerulonephritis Induced by Anti-
MPO IgG and LPS
To investigate the involvement of TNF- in the LPS-me-
diated aggravation of anti-MPO IgG-induced glomerulo-
Figure 2. Effect of LPS on renal tissue injury in C57BL/6 mice 6 days after passive transfer of anti-MPO IgG. A: Overview of renal tissue of a mouse that received
anti-MPO IgG. One small crescentic glomerulus is shown (arrow). B: Overview of renal tissue in a mouse that received anti-MPO IgG and 0.5 g/g LPS. Increased
numbers of crescentic glomeruli are observed (arrows). C: Segmental fibrinoid necrosis in a glomerulus from a mouse that received anti-MPO IgG. D: Small
cellular crescent in a mouse that received anti-MPO IgG. E: Glomerulus with segmental fibrinoid necrosis and crescent formation in a mouse that received
anti-MPO IgG. F: Segmental fibrinoid necrosis in a glomerulus from a mouse that received anti-MPO IgG and 0.5 g/g LPS. G: Large cellular crescent in mouse
that received anti-MPO IgG and 0.5 g/g LPS. H: Large cellular crescent with breaks in Bowman’s capsule and periglomerular accumulation of inflammatory cells
in a mouse that received anti-MPO IgG and 0.5 g/g LPS. A, B, D, E, G, H: PAS stain; C, F: H&E stain. Original magnifications: 320 (A, B); 400 (C–H).
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nephritis, a neutralizing anti-murine TNF- antibody (TN3)
was used. In these experiments, mice received an intra-
peritoneal injection of 500 g TN3 or isotype control on
day 1, followed by administration of anti-MPO IgG and
0.5 g/g LPS on day 0. In both groups, mice developed
hematuria and leukocyturia to a similar degree as mea-
sured by dipstick analysis. However, pathological analy-
sis at day 6 revealed that pretreatment with TN3 sig-
nificantly attenuated glomerular crescent formation,
whereas no difference was found in the extent of glomer-
ular necrosis (Figure 6). In both groups, renal function on
day 6 was unimpaired (blood urea nitrogen 7.8  1.4
versus 7.4  2.1 and creatinine 19. 4.1 versus 19.3 
1.9 in TN3 and isotype control antibody-treated mice,
respectively). Immunohistochemical analysis showed
that pretreatment with TN3 significantly attenuated glo-





macrophages CD3 T cells PMNs
Anti-MPO 5 1.82  0.19 1.34  0.13 0.44  0.20 0.39  0.10
Anti-MPO  5 g/g LPS 5 3.72  0.51* 2.24  0.07* 0.55  0.14 0.48  0.19
Anti-MPO  0.5 g/g LPS 5 3.56  0.41* 2.45  0.19* 0.43  0.14 0.39  0.10
Anti-MPO  0.05 g/g LPS 4 1.95  0.14 1.48  0.22 0.23  0.03 0.21  0.07
LPS 5 g/g 4 1.08  0.10 0.44  0.15 0.31  0.13 0.22  0.08
WT 4 0.77  0.26 0.36  0.20 0.17  0.06 0.09  0.07
*P  0.0001 compared to anti-MPO alone. Numbers represent mean numbers  SD of positive cells per glomerular cross section.
Figure 3. Effect of LPS on inflammatory cell recruitment in C57BL/6 mice 6 days after passive transfer of anti-MPO IgG. A: Moderate intraglomerular and interstitial
infiltration of CD45ve leukocytes in a mouse that received anti-MPO IgG. B: Intra- and periglomerular influx of FA11ve macrophages in a mouse that received
anti-MPO IgG. C and D: Marked intra- and periglomerular and interstitial influx of CD45ve leukocytes in a mouse that received anti-MPO IgG and 0.5 g/g LPS.
E and F: Marked intra- and periglomerular and interstitial influx of FA11ve macrophages in a mouse that received anti-MPO IgG and 0.5 g/g LPS. G:
Immunofluorescent staining for MPO in a mouse that received anti-MPO IgG and 0.5 g/g LPS. H: Immunofluorescent staining for mouse IgG in a mouse that
received anti-MPO IgG and 0.5 g/g LPS. I: Immunofluorescent staining for fibrin in a mouse that received anti-MPO IgG and 0.5 g/g LPS showing prominent
staining corresponding to crescent formation. Original magnifications: 200 (A, B, D, E); 630 (C, F); 400 (G–I).
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merular influx of CD45 total leukocytes and FA11 mac-
rophages (Table 4). No differences were observed in
intraglomerular numbers of neutrophils and T cells (Table
4). By immunofluorescence, glomerular IgG staining was
absent or scanty in both groups.
Anti-MPO IgG Induces Superoxide Anion
Production in TNF--Primed Peritoneal
Exudate Cells in Vitro
The capacity of anti-MPO antibodies to induce neutrophil
activation in vitro was determined using the SOD inhibit-
able ferricytochrome C assay. Incubation of unprimed
peritoneal exudate cells with normal mouse IgG or anti-
MPO IgG did not induce superoxide production above
background (data not shown). However, when peritoneal
exudate cells were pretreated with 10 ng/ml of murine
TNF- for 10 minutes, incubation with anti-MPO IgG re-
sulted in a modest but significant increase in superoxide
production as compared to normal mouse IgG or buffer
alone (Figure 7, A and B). Importantly, anti-MPO IgG did
not induce superoxide anion production in TNF--
primed, MPO-deficient peritoneal exudate cells (Figure 7,
Figure 4. Effect of LPS on neutrophil influx and aggregation in C57BL/6
mice 1 day after passive transfer of anti-MPO IgG. A: Glomerulus from a
mouse that received anti-MPO IgG showing segmental neutrophil influx
and formation of a small neutrophilic aggregate. B: Glomerulus from a
mouse that received anti-MPO and 0.5 g/g LPS showing massive neu-
trophil influx and homotypic aggregation. C and D: Quantification of
glomerular neutrophil influx (C) and the percentage of glomeruli that
contained homotypic neutrophil aggregates (D) in mice (n  3 in each
group) that received LPS (0.5 g/g) alone, anti-MPO IgG alone, or
anti-MPO and LPS (0.5 g/g). gcs, glomerular cross-section. *P  0.008.
Original magnifications, 400 (A and B).
Figure 5. Serum MPO and TNF- levels in C57BL/6 mice that received 0.05
(white bars), 0.5 (gray bars), or 5 g/g (black bars) of LPS by intraperi-
toneal injection. The horizontal line indicates the mean serum MPO levels
in serum samples taken before treatment. In these pretreatment samples, no
TNF- could be detected.
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A and C). Phorbol ester myristate acetate-induced super-
oxide anion production in these cells was, however, sim-
ilar to that observed in WT peritoneal exudate cells
(Figure 7A).
Discussion
In the present study, three main findings are reported that
are relevant to the pathogenesis of MPO-ANCA-induced
glomerulonephritis. First, it was demonstrated that sys-
temic administration of bacterial LPS markedly aggra-
vates anti-MPO-induced NCGN. This effect was depen-
dent on the dose of LPS administered and appeared to
be related to LPS-induced circulating levels of TNF- and
MPO. Second, LPS-mediated aggravation of anti-MPO
IgG-induced glomerulonephritis was attenuated, but not
prevented, by pretreatment with neutralizing anti-TNF-
antibodies. Finally, in vitro experiments showed that mu-
rine anti-MPO IgG induces an oxidative burst in TNF--
primed peritoneal exudate cells, an observation that is
consistent with human data showing ANCA mediated
neutrophil activation.
In our studies, glomerulonephritis induction by anti-
MPO IgG alone is less severe compared to similar groups
of mice reported in the companion paper by Xiao and
colleagues. The most plausible explanation for this differ-
ence in disease severity is the route of injection of the
anti-MPO antibodies. In our studies, anti-MPO antibodies
were injected intraperitoneally whereas in the companion
article the antibodies were administered intravenously.
This could potentially lead to different levels of circulating
anti-MPO antibodies but we have not formally tested this.
Another explanation may be that the antibody batches
used in these two studies differed in the amount of patho-
genic anti-MPO antibodies. Importantly, however, in both
studies, transfer of anti-MPO antibodies induced cres-
centic glomerulonephritis in all of the tested mice, which
emphasizes the pathogenic potential of these autoanti-
bodies. Our observation that LPS dose dependently ag-
gravates anti-MPO-induced glomerulonephritis provides
support for the hypothesis that ANCAs and proinflamma-
tory stimuli act synergistically in inducing full-blown dis-
ease in humans. With respect to the mechanisms under-
lying this effect several possibilities may be considered
and will be discussed below.
First, as shown here and by many others, systemic
administration of LPS results in an immediate, transient
increase in serum TNF- levels. From in vitro experiments
on human polymorphonuclear leukocytes, it is well known
that priming with TNF- is necessary for the induction of
a respiratory burst by sera or purified IgG from ANCA-
positive patients.10–15 We confirmed this in our mouse
model by showing that anti-MPO IgG induced an oxida-
tive burst in peritoneal exudate cells only after pretreat-
ment with TNF-, and only when those cells were ob-
tained from MPO-competent mice. Second, we observed
that administration of LPS synergistically increased anti-
MPO IgG-induced early glomerular neutrophil recruit-
ment. The number of infiltrating polymorphonuclear leu-
kocytes was significantly increased in anti-MPO-treated
mice with or without LPS that were sacrificed 1 day after
disease induction. These results suggest an important
role for polymorphonuclear leukocytes in the initiation of
anti-MPO IgG-induced disease. The number of lesional
polymorphonuclear leukocytes had decreased on day 6,
which most likely is a reflection of the progression of the
inflammatory response that is dominated by macro-
phages. This is in line with in vitro data, demonstrating an
Table 4. Immunophenotyping of Intraglomerular Inflammatory Cell Infiltrate at 6 Days after Anti-TNF- Antibody or Isotype





macrophages CD3 T cells PMNs
Anti-MPO  0.5 g/g LPS  L2-3D9 8 3.03  0.52* 2.26  0.62* 0.33  0.14 0.37  0.10
Anti-MPO  0.5 g/g LPS  TN3 7 2.23  0.41 1.53  0.29 0.37  0.08 0.35  0.14
*P  0.005 compared to anti-MPO  0.5 g/g LPS  TN3. Numbers represent mean numbers  SD of positive cells per glomerular cross section.
Figure 6. Effect of anti-TNF- treatment on NCGN induced by anti-MPO IgG and LPS (0.5 g/g). A: Quantification of glomerular crescent formation on anti-TNF-
or isotype control treatment. Glomerular crescent formation is expressed as a percentage of glomerular crescents in each animal. B: Quantification of glomerular
necrosis on anti-TNF- or isotype control treatment. Glomerular necrosis is expressed as a percentage of glomeruli with necrosis in each animal.
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important role for priming of endothelial cells with TNF-
25 or LPS26 in anti-MPO IgG-induced neutrophil adhe-
sion. Subsequently, these adherent neutrophils may be-
come activated by MPO-ANCA causing endothelial cell
injury.27 Despite aggravation of renal injury by LPS as
observed by histopathological analysis, renal function in
these mice was not impaired. Apparently, the number of
affected glomeruli was not sufficient to cause elevations
in serum creatinine and blood urea nitrogen levels.
The requirement for TNF- priming in ANCA-mediated
neutrophil activation is in part explained by the observa-
tion that primed neutrophils translocate the ANCA anti-
gens to their cell surface making them accessible for
interaction with the autoantibodies. In the case of MPO-
ANCA, studies have clearly demonstrated that expres-
sion of MPO is essential for MPO-ANCA-mediated neu-
trophil activation because neutrophils obtained from
MPO-deficient individuals are nonresponsive.28 How-
ever, inconsistent data exist on whether MPO-ANCA-
mediated neutrophil activation involves MPO expressed
on the cell surface of primed neutrophils. Whereas some
authors describe an enhanced surface expression of
MPO on primed neutrophils, others have been unable to
demonstrate this effect.10,12,13,15 In preliminary experi-
ments using flow cytometry, we have not been able to
convincingly demonstrate surface MPO expression on
either peripheral neutrophils from LPS-treated mice or
peritoneal exudate cells treated with LPS in vitro. One
possibility is that priming induces cell surface MPO ex-
pression in minute amounts that are below the detection
limits of our assay system but this clearly needs further
investigation. Alternatively, other mechanisms may be
involved in MPO-ANCA-mediated neutrophil activation.
Studies by Hess and colleagues10 have shown that rest-
ing human neutrophils exposed to supernatants of de-
granulated autologous neutrophils expressed MPO, but
not Pr3, on their cell surface and became responsive to
anti-MPO autoantibodies. Interestingly, high levels of cir-
culating MPO correlate with disease severity in human
MPO-ANCA-associated glomerulonephritis.8 In the
present study, we found that doses of LPS that aggra-
vated anti-MPO IgG-induced glomerulonephritis also
gave rise to increased levels of circulating MPO. Based
on these observations we speculate that circulating MPO,
in the presence of high levels of anti-MPO antibodies,
may disperse MPO-ANCA-mediated activation to resting
Figure 7. A: Superoxide anion production in TNF- (10 ng/ml)-primed
peritoneal exudate cells (4  105 cells/well) derived from WT C57BL/6 or
Mpo/ mice as measured by the SOD inhibitable ferricytochrome C assay.
Anti-MPO IgG (250 g/ml) induces significant superoxide anion production
in TNF--primed peritoneal exudate cells from WT C57BL/6 mice (black
bars) as compared to normal mouse IgG (250 g/ml) or buffer alone. In
contrast, no superoxide anion production was detected in TNF--primed
peritoneal exudate cells from MPO/ mice (white bars) on stimulation
with anti-MPO IgG. Results represent mean OD 550 nm  SD of three to
four experiments performed in triplicate. *P  0.02 compared to anti-MPO
IgG on MPO-deficient cells. B and C: Time course of superoxide anion
production in response to phorbol ester myristate acetate (, 200 ng/ml),
anti-MPO IgG (Œ, 250 g/ml), normal mouse IgG (, 250 g/ml), or buffer
alone (F) using TNF--primed peritoneal exudate cells from WT C57BL6 (B)
or Mpo/ mice (C). Results represent mean OD 550 nm from single
experiments performed in triplicate.
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neutrophils resulting in amplification of the inflammatory
response.
As described above, ANCA-induced neutrophil activa-
tion is enhanced on priming with proinflammatory stimuli,
in particular TNF-. This is a potent proinflammatory cy-
tokine produced by many cell types, and there is mount-
ing evidence that TNF- plays a major role in glomerular
inflammation and scarring.29 The actions of TNF- are
numerous and include the stimulation of release of other
cytokines and chemokines, and the induction of adhesion
molecule expression on the endothelium.30 To directly
investigate the contribution of TNF- on the LPS-medi-
ated aggravation of anti-MPO IgG-induced glomerulone-
phritis, we treated mice with a neutralizing anti-TNF-
antibody before disease induction. It was found that
TNF- -inhibition reduced glomerular crescent formation
whereas development of glomerular necrosis was unaf-
fected. These results are in agreement with studies in
TNF--deficient mice, in which the development of accel-
erated anti-glomerular basement antibody (GBM) glo-
merulonephritis is also attenuated but not completely
prevented.31 On the other hand, complete prevention of
glomerular crescent formation has been observed in a rat
model of anti-GBM glomerulonephritis on treatment with
the soluble TNF- receptor P55.32 Our observations sug-
gest that, as yet unknown, TNF--independent effects
also play a role in the LPS-mediated aggravation of anti-
MPO IgG-induced glomerulonephritis but this clearly
needs to be investigated in more detail.
In conclusion, the results of the present study are in
agreement with the hypothesis that in ANCA-associated
diseases, autoantibody-mediated effects and proinflam-
matory signals synergize in causing vascular inflamma-
tion by promoting neutrophil adhesion to the endothelium
and enhancing neutrophil activation. Furthermore, our
findings indicate that therapeutic strategies aimed at
neutralizing TNF- bioactivity could be beneficial in the
treatment of ANCA-associated diseases. In fact, such
clinical studies have already been initiated and in a first
preliminary publication, promising results have been
reported.33
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